Corteva initiated with a Buy at Canaccord

Canaccord analyst Bobby Burleson initiated coverage of Corteva with a Buy rating and $75 price target. Innovations across Ag inputs and equipment should provide key pillars for necessary change, and while Corteva is a leading incumbent within the conventional farming system, it is also an Ag Biotech leader, and its innovations are helping drive a transition to sustainable agricultural production, the analyst tells investors in a research note. With its seed trait technology and expanding biologics portfolio seeing healthy adoption, the firm sees attractive revenue and profitability growth ahead.